Drug Trial Radar · NCT05192200
An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study
Last checked: Nov 20, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 20, 2021
Primary completion
Nov 20, 2023
Study completion Nov 20, 2023
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.
Conditions
- Dermatomyositis
Interventions
Anti-Beta Interferon (PF-06823859)Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From Day 1 of dosing maximum up to Week 68
- Number of Participants With Laboratory AbnormalitiesTime frame: From Day 1 of dosing maximum up to Week 68
- Number of Participants According to Categorization of Changes in Vital SignsTime frame: From Day 1 of dosing maximum up to Week 68
- Number of Participants According to Categorization of Electrocardiogram (ECG) FindingsTime frame: From Day 1 of dosing maximum up to Week 68
Locations
25 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Alabama at Birmingham, Department of Dermatology
Birmingham, Alabama
Mayo Clinic
Scottsdale, Arizona
Attune Health Research Inc.
Beverly Hills, California
Mayo Clinic in Florida
Jacksonville, Florida
KU Clinical Research Center - Clinical and Translational Science Unit (CTSU)
Fairway, Kansas
KU Clinical and Translational Science Unit (CTSU) Rainbow
Kansas City, Kansas
University of Kansas Medical Center
Kansas City, Kansas
Brigham & Women's Hospital
Boston, Massachusetts
Brigham and Women's Hospital - CTH
Boston, Massachusetts
Center for Outpatient Health
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
NYU Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology
New York, New York
NYU Langone Health Clinical Research Center
New York, New York
NYU Langone Radiology - Ambulatory Care Center East 41st Street
New York, New York
Mount Sinai Doctors Dermatology
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Cleveland Clinic Foundation
Cleveland, Ohio
Center for Human Phenomic Science
Philadelphia, Pennsylvania
University of Pennsylvania, Perelman Center for Advanced Medicine (PCAM)
Philadelphia, Pennsylvania
Debreceni Egyetem Klinikai Kozpont
Debrecen, Hungary
Centrum Medyczne Plejady
Krakow, Poland
Nova Reuma Społka Partnerska
Bialystok, Podlaskie Voivodeship, Poland
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.